Literature DB >> 22293826

A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats.

Aashish S Morani1, Susan Schenk, Thomas E Prisinzano, Bronwyn Maree Kivell.   

Abstract

Kappa opioid receptor (KOPr) activation antagonizes many cocaine-related behaviors but adverse side-effects such as sedation, dysphoria, and depression limit their therapeutic use. Recently, salvinorin A (Sal A), a naturally occurring KOPr agonist, has been shown to attenuate cocaine-induced drug seeking in a model of relapse in rats. The present study evaluated the effects of acute Sal A exposure on cocaine-induced hyperactivity and cocaine sensitization in rats. Acute treatment with a dose of Sal A that decreased drug seeking in a previous study (0.3 mg/kg) significantly attenuated the expression of cocaine sensitization. This dose of Sal A failed to affect spontaneous locomotion or to produce a conditioned taste aversion to a novel-tasting saccharin solution. However, Sal A decreased climbing and swimming time and increased time spent immobile in the forced swim test. These findings indicate that Sal A, just like traditional KOPr agonists, attenuates cocaine-induced behavioral sensitization but does not produce the adverse effect of conditioned aversion, suggesting improved potential compliance. However, prodepressive effects were also produced and these effects may limit the therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293826      PMCID: PMC3306836          DOI: 10.1097/FBP.0b013e3283512c1e

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  81 in total

Review 1.  Legally high? Legal considerations of Salvia divinorum.

Authors:  O Hayden Griffin; Bryan Lee Miller; David N Khey
Journal:  J Psychoactive Drugs       Date:  2008-06

2.  Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.

Authors:  Daniela Braida; Valeria Limonta; Simona Pegorini; Alessia Zani; Chiara Guerini-Rocco; Enzo Gori; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

3.  Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

Authors:  Eduardo R Butelman; Marek Mandau; Kevin Tidgewell; Thomas E Prisinzano; Vadim Yuferov; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2006-10-23       Impact factor: 4.030

Review 4.  Salvinorin A: from natural product to human therapeutics.

Authors:  Timothy A Vortherms; Bryan L Roth
Journal:  Mol Interv       Date:  2006-10

5.  Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.

Authors:  Daniela Braida; Valeria Limonta; Valeria Capurro; Paola Fadda; Tiziana Rubino; Paola Mascia; Alessia Zani; Enzo Gori; Walter Fratta; Daniela Parolaro; Mariaelvina Sala
Journal:  Biol Psychiatry       Date:  2007-10-24       Impact factor: 13.382

6.  Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.

Authors:  Jacob M Hooker; Youwen Xu; Wynne Schiffer; Colleen Shea; Pauline Carter; Joanna S Fowler
Journal:  Neuroimage       Date:  2008-03-15       Impact factor: 6.556

7.  The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.

Authors:  Catherine B Willmore-Fordham; Daniel M Krall; Christopher R McCurdy; David H Kinder
Journal:  Neuropharmacology       Date:  2007-06-27       Impact factor: 5.250

Review 8.  Dynorphin and the pathophysiology of drug addiction.

Authors:  T S Shippenberg; A Zapata; V I Chefer
Journal:  Pharmacol Ther       Date:  2007-07-24       Impact factor: 12.310

9.  Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.

Authors:  Brenda J Gehrke; Vladimir I Chefer; Toni S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  2008-02-02       Impact factor: 4.530

10.  Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats.

Authors:  Elena H Chartoff; David Potter; Diane Damez-Werno; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

View more
  13 in total

1.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

2.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

Review 3.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

4.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

5.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

6.  Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Authors:  C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-31       Impact factor: 4.530

7.  The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.

Authors:  Amy W M Ewald; Peter J Bosch; Aimee Culverhouse; Rachel Saylor Crowley; Benjamin Neuenswander; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Psychopharmacology (Berl)       Date:  2017-05-23       Impact factor: 4.530

Review 8.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

9.  Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion.

Authors:  Yuan-Yuan Wei; Yan Ma; Song-Yu Yao; Ling-Hui Kong; Xiao Liu; Jing-Rui Chai; Jing Chen; Wei Li; Yu-Jun Wang; Li-Ming Shao; Jing-Gen Liu
Journal:  Acta Pharmacol Sin       Date:  2021-09-07       Impact factor: 7.169

10.  Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

Authors:  B Simonson; A S Morani; A W M Ewald; L Walker; N Kumar; D Simpson; J H Miller; T E Prisinzano; B M Kivell
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.